American Renal Associates Holdings, Inc (ARA) Expected to Post FY2017 Earnings of $0.59 Per Share

American Renal Associates Holdings, Inc (NYSE:ARA) – Equities researchers at Leerink Swann raised their FY2017 earnings estimates for American Renal Associates Holdings in a research note issued on Tuesday. Leerink Swann analyst A. Gupte now expects that the company will post earnings per share of $0.59 for the year, up from their prior forecast of $0.54. Leerink Swann currently has a “Outperform” rating and a $17.00 price target on the stock. Leerink Swann also issued estimates for American Renal Associates Holdings’ Q4 2017 earnings at $0.18 EPS, FY2018 earnings at $0.79 EPS, FY2019 earnings at $0.93 EPS and FY2020 earnings at $1.06 EPS.

A number of other equities analysts have also commented on ARA. SunTrust Banks, Inc. set a $18.00 price objective on shares of American Renal Associates Holdings and gave the company a “buy” rating in a research report on Sunday, October 15th. Zacks Investment Research upgraded shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Thursday, November 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $17.75.

COPYRIGHT VIOLATION NOTICE: This article was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/11/24/american-renal-associates-holdings-inc-ara-expected-to-post-fy2017-earnings-of-0-59-per-share.html.

American Renal Associates Holdings (ARA) opened at $13.10 on Wednesday. The company has a debt-to-equity ratio of 3.57, a current ratio of 1.16 and a quick ratio of 1.13. American Renal Associates Holdings has a 1 year low of $9.91 and a 1 year high of $24.94. The company has a market cap of $412.14, a P/E ratio of 19.55, a PEG ratio of 1.16 and a beta of 3.64.

American Renal Associates Holdings (NYSE:ARA) last released its quarterly earnings data on Tuesday, November 14th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. American Renal Associates Holdings had a negative net margin of 2.15% and a positive return on equity of 15.80%. The company had revenue of $187.71 million during the quarter, compared to analyst estimates of $194.60 million. During the same period last year, the business earned $0.28 earnings per share. American Renal Associates Holdings’s revenue was down 2.7% compared to the same quarter last year.

Several hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. lifted its position in American Renal Associates Holdings by 1,876.9% during the second quarter. Citigroup Inc. now owns 8,046 shares of the company’s stock valued at $149,000 after purchasing an additional 7,639 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in American Renal Associates Holdings by 19.7% during the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock valued at $162,000 after purchasing an additional 1,443 shares during the last quarter. Citadel Advisors LLC bought a new stake in American Renal Associates Holdings during the third quarter valued at approximately $200,000. Dimensional Fund Advisors LP bought a new stake in American Renal Associates Holdings during the second quarter valued at approximately $230,000. Finally, Rhumbline Advisers lifted its position in American Renal Associates Holdings by 2.7% during the second quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock valued at $248,000 after purchasing an additional 354 shares during the last quarter. Institutional investors own 92.91% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Earnings History and Estimates for American Renal Associates Holdings (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply